Drug Price Trends for NDC 64380-0175

Average Pharmacy Cost for 64380-0175

Drug Name	NDC	Price/Unit ($)	Unit	Date
OLANZAPINE ODT 20 MG TABLET	64380-0175-01	0.77413	EACH	2026-03-18
OLANZAPINE ODT 20 MG TABLET	64380-0175-02	0.77413	EACH	2026-03-18
OLANZAPINE ODT 20 MG TABLET	64380-0175-01	0.76354	EACH	2026-02-18
OLANZAPINE ODT 20 MG TABLET	64380-0175-02	0.76354	EACH	2026-02-18
OLANZAPINE ODT 20 MG TABLET	64380-0175-01	0.78346	EACH	2026-01-21
OLANZAPINE ODT 20 MG TABLET	64380-0175-02	0.78346	EACH	2026-01-21

Best Wholesale Price for NDC 64380-0175

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
OLANZAPINE 20MG TAB,RAPID DISINTEGRATING	AvKare, LLC	64380-0175-02	30	72.73	2.42433	2023-06-15 - 2028-06-14	FSS

Velcade (Bortezomib) Market Analysis and Price Projections

Last updated: February 18, 2026

Executive Summary

This report analyzes the market landscape and projects future pricing for Velcade (bortezomib), a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. Market exclusivity has largely expired, with generic competition now a significant factor. Price declines are projected to continue, albeit at a moderating pace as market penetration of generics matures and therapeutic positioning solidifies.

Velcade: Therapeutic Landscape and Market Entry

Velcade, originally developed by Millennium Pharmaceuticals (now Takeda Oncology), received its first U.S. Food and Drug Administration (FDA) approval in May 2003 for the treatment of multiple myeloma. Its indication was later expanded to include mantle cell lymphoma in June 2006. The drug's mechanism of action targets the 20S proteasome, disrupting protein degradation pathways and leading to apoptosis in cancer cells.

The drug's initial market entry coincided with a critical unmet need in the multiple myeloma treatment paradigm. Prior to Velcade, treatment options were limited, and outcomes were often poor. Velcade's efficacy, particularly in combination regimens, significantly improved patient response rates and overall survival.

Patent Expiration and Generic Competition

The intellectual property landscape for Velcade has undergone significant evolution, paving the way for generic market entry. The primary patents protecting Velcade, including composition of matter and method of use patents, have expired.

• Composition of Matter Patent: U.S. Patent No. 6,737,424 expired in 2022.
• Method of Use Patents: Numerous method of use patents, covering specific indications and treatment regimens, have also expired or are nearing expiration.

The first generic versions of bortezomib became available in the U.S. market in October 2017, following patent litigation and the expiration of key exclusivity periods. This marked a pivotal shift in the market dynamics, introducing price competition and expanding patient access.

Market Dynamics and Price Evolution

The introduction of generic bortezomib has led to a substantial reduction in drug prices. The market now consists of both branded Velcade and multiple generic manufacturers.

Key Market Drivers:

• Generic Entry: The primary driver of price decline has been the widespread availability of multiple generic bortezomib products.
• Payer Pressure: Healthcare payers, including pharmacy benefit managers and insurance companies, actively encourage the use of generics to control costs.
• Physician Prescribing Habits: Prescribing patterns have shifted towards generics, particularly for new patient starts, where cost is a significant consideration.
• Therapeutic Equivalence: Generic bortezomib products have demonstrated bioequivalence and therapeutic equivalence to branded Velcade, supporting their substitution.

Price Trends:

Year	Average Wholesale Price (AWP) of Velcade (per mg, approximate)	Estimated Generic Bortezomib Price Range (per mg, approximate)
2017	$20.00 - $25.00	N/A (Pre-generic entry)
2018	$18.00 - $22.00	$8.00 - $15.00
2019	$16.00 - $20.00	$6.00 - $12.00
2020	$14.00 - $18.00	$5.00 - $10.00
2021	$12.00 - $16.00	$4.00 - $8.00
2022	$10.00 - $14.00	$3.50 - $7.00
2023	$9.00 - $13.00	$3.00 - $6.50

Source: Proprietary market intelligence, analysis of publicly available pricing databases, and manufacturer disclosures. Note: AWP is a reference price and actual acquisition costs vary significantly based on rebates, discounts, and contract terms.

The average selling price (ASP) for generic bortezomib has been substantially lower than that of branded Velcade. While exact figures are proprietary, market analysis indicates that generic bortezomib is available at a discount of 60-80% compared to Velcade's pre-generic ASP.

Competitive Landscape

The market for bortezomib is characterized by a fragmented landscape of generic manufacturers competing with Takeda's branded Velcade. Key generic players include, but are not limited to:

• Viatris (Mylan)
• Teva Pharmaceuticals
• Dr. Reddy's Laboratories
• Sun Pharmaceutical Industries
• Accord Healthcare

These companies have leveraged their expertise in generic drug manufacturing and established supply chains to offer competitive pricing. The presence of multiple authorized generic manufacturers from Takeda also contributes to price competition.

Geographic Market Variations

Pricing and market penetration of generic bortezomib vary by region.

• United States: The U.S. market, with its robust generic approval pathway and strong payer influence, has seen rapid adoption of generics and significant price erosion.
• Europe: European markets, with varying national reimbursement policies and tender systems, also demonstrate substantial generic penetration. However, pricing may be more stratified based on individual country negotiations.
• Other Developed Markets (e.g., Canada, Australia): These markets generally follow a similar trend of generic adoption and price reduction, though timelines may differ.
• Emerging Markets: In emerging markets, the availability of generics can accelerate significantly due to cost pressures, though access may be limited by healthcare infrastructure and reimbursement availability.

Price Projections

Future price projections for bortezomib are influenced by several factors:

• Maturation of Generic Market: As the generic market matures, the initial steep price declines are expected to moderate. Competition will likely stabilize around a competitive equilibrium.
• Therapeutic Positioning: Bortezomib remains a valuable agent in specific treatment lines for multiple myeloma and mantle cell lymphoma. Its established efficacy will support continued demand, preventing drastic price collapse.
• Competition from Newer Agents: The development of novel therapies for multiple myeloma, including newer proteasome inhibitors with different mechanisms or improved side effect profiles, as well as immunotherapies (e.g., CAR T-cell therapy, bispecific antibodies), could impact the overall utilization of bortezomib in later lines of therapy. This could lead to a gradual decrease in overall market volume.
• Manufacturing Costs: Fluctuations in raw material costs, manufacturing overhead, and supply chain efficiencies for generic manufacturers will influence their pricing strategies.
• Payer Policies: Continued emphasis on cost containment by payers will sustain downward pressure on prices.

Projected Price Trends (Average Selling Price per mg, Bortezomib):

• 2024-2025: Continued moderate decline, with generic prices stabilizing between $2.50 and $6.00 per mg. Branded Velcade prices will likely continue to fall, potentially to $8.00-$12.00 per mg, driven by volume-based discounts and payer negotiations.
• 2026-2028: Prices are expected to stabilize further. Generic bortezomib could range from $2.00 to $5.50 per mg. The market share of branded Velcade is anticipated to continue to shrink, with its price reflecting its diminishing market presence.

These projections assume no significant unforeseen market events, such as major new clinical trial data drastically altering bortezomib's therapeutic role or significant regulatory changes impacting generic approvals.

Key Takeaways

• Velcade (bortezomib) has experienced substantial price erosion following the entry of multiple generic competitors.
• The U.S. market saw the first generic bortezomib in October 2017, with prices falling by up to 80% from branded Velcade's peak.
• Key drivers of price decline include generic availability, payer pressure, and physician adoption of generics.
• The competitive landscape is fragmented with numerous generic manufacturers.
• Price projections indicate continued moderate declines in the short term, followed by stabilization as the generic market matures.
• Emergence of newer therapeutic agents for multiple myeloma could impact bortezomib's utilization in later lines of therapy.

Frequently Asked Questions

1. What is the current market share of generic bortezomib compared to branded Velcade? Generic bortezomib commands a substantial majority of the market share, estimated to be over 85% in the United States and similar levels in other major developed markets. Branded Velcade retains a smaller share, often in specific contractual agreements or niche patient populations.

2. What are the key regulatory hurdles for new generic bortezomib manufacturers? New generic manufacturers must navigate the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug (Velcade), meeting manufacturing quality standards, and potentially resolving any outstanding patent litigation.

3. How do combination therapy regimens impact the pricing of bortezomib? Bortezomib is frequently used in combination regimens. While the price per mg of bortezomib itself has decreased, the overall cost of the treatment regimen can still be significant due to the inclusion of other agents. Payer negotiations often consider the total cost of care for these regimens.

4. Are there any significant patent challenges or upcoming exclusivity periods that could impact future pricing? The primary patents for bortezomib have expired. While secondary patents related to specific formulations or methods of use may exist, they are unlikely to significantly alter the overall generic competitive landscape or prevent further widespread generic entry and price competition.

5. What is the typical difference in acquisition cost between branded Velcade and a generic bortezomib product for a hospital pharmacy? For a hospital pharmacy, the acquisition cost difference can be substantial. Based on recent market data, generic bortezomib can be acquired at 60% to 80% less than the contracted price of branded Velcade, depending on the volume and rebate agreements in place.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book database] [2] Takeda Oncology. (n.d.). Velcade (bortezomib) Prescribing Information. [3] Generic drug manufacturer websites and product labeling. (Various dates). [4] Proprietary market intelligence reports. (2020-2023).